KAE609 [(19R,39S)-5,79-dichloro-69-fluoro-39-methyl-29,39,49,99-tetrahydrospiro[indoline-3,19-pyridol[3,4-b]indol]-2-one] is a potent, fast-acting, schizonticidal agent in clinical development for the treatment of malaria. This study investigated the absorption, distribution, metabolism, and excretion of KAE609 after oral administration of [ 14 C]KAE609 in healthy subjects. After oral administration to human subjects, KAE609 was the major radioactive component (approximately 76% of the total radioactivity in plasma); M23 was the major circulating oxidative metabolite (approximately 12% of the total radioactivity in plasma). Several minor oxidative metabolites (M14, M16, M18, and M23.5B) were also identified, each accounting for approximately 3%-8% of the total radioactivity in plasma. KAE609 was well absorbed and extensively metabolized, such that KAE609 accounted for approximately 32% of the dose in feces. The elimination of KAE609 and metabolites was primarily mediated via biliary pathways. M23 was the major metabolite in feces. Subjects reported semen discoloration after dosing in prior studies; therefore, semen samples were collected once from each subject to further evaluate this clinical observation. Radioactivity excreted in semen was negligible, but the major component in semen was M23, supporting the rationale that this yellow-colored metabolite was the main source of semen discoloration. In this study, a new metabolite, M16, was identified in all biologic matrices albeit at low levels. All 19 recombinant human cytochrome P450 enzymes were capable of catalyzing the hydroxylation of M23 to form M16 even though the extent of turnover was very low. Thus, electrochemistry was used to generate a sufficient quantity of M16 for structural elucidation. Metabolic pathways of KAE609 in humans are summarized herein and M23 is the major metabolite in plasma and excreta.
Introduction
Human malaria can be caused by five protozoan parasites of the plasmodia genera but the majority of all cases are attributable to either Plasmodium falciparum or Plasmodium vivax. After a bite from an infected mosquito, the parasite infects hepatocytes and subsequently erythrocytes in the human host. It is the blood parasitemia (the schizont form) and erythrocyte rupture that produces the acute clinical symptoms (spiking fever, rigors, malaise, headache, muscle aches) and vascular compromise and organ involvement, which results in complications that can be fatal. P. falciparum is more commonly associated with severe forms of malaria. P. vivax, unlike P. falciparum, maintains a hepatic reserve that can result in subsequent clinical relapses after successful treatment of the parasitemia.
Drug resistance has occurred with prior therapies developed for malaria and it has been detected to a limited extent for the artemisinin class (Carter et al., 2015; Hott et al., 2015) . Despite the current emphasis on sole use of combination therapies, it is predicted that, given the current detection in clinical settings of artemisinin resistance, widespread artemisinin drug resistance will occur, as has been the historical experience for prior antimalarials. Therefore, there is an urgent medical need for the development of new antimalarial nonartemisinin-based drugs.
KAE609 [(19R,39S)-5,79-dichloro-69-fluoro-39-methyl-29,39,49,99-tetrahydrospiro[indoline-3,19-pyridol[3,4-b] indol]-2-one] (Fig. 1) , a spiroindolone, represents a new class of potent, fast-acting, schizonticidal agents Yeung et al., 2010; Meister et al., 2011; Spillman et al., 2013) . KAE609 was safe and well tolerated in healthy subjects up to the highest tested single dose of 300 mg and the highest tested multiple dose of 150 mg daily for 3 days (Leong et al., 2014) . Evaluation in 21 evaluable adult patients with uncomplicated malaria due to either P. vivax (n = 10) or P. falciparum (n = 11) showed that once-daily dosing of KAE609 at 30 mg for 3 days was well tolerated and resulted in a rapid median parasite clearance time of approximately 12 hours for both P. vivax and P. falciparum (White et al., 2014) . The median fever clearance time was 8 hours and 12 hours for P. vivax and P. falciparum, respectively. The preliminary parasite clearance time and fever clearance time results place KAE609 in the same range as the standard-of-care artemisinin class of antimalarials such as the combination therapy artemether/lumefantrine (Coartem).
To facilitate the understanding of metabolism KAE609, we conduted absorption, distribution, metabolism, and excretion (ADME) studies in nonclinical species (Huskey et al., 2016) . Three prominent metabolites (M37, M18, and M23) were identified in biologic matrices (Fig. 1) . Despite M23 being the major metabolite in dog feces, M23 was not detected in either rat or dog plasma. In contrast, M23 was identified in initial human studies to be a metabolite in plasma. In view of potential metabolite safety coverage concerns (see U.S. Food and Drug Administration 2008 , and 2012 guidance, available at http:// www.fda.gov/cder/guidance/index.htm and http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm), our strategy was to conduct an investigation of human ADME during early development to define the metabolic pathways of KAE609, elucidate potential preclinical safety exposure concerns, and determine the potential effect of intrinsic and extrinsic factors on KAE609. A single oral dose of 300 mg [ 14 C]KAE609 (65 mCi) in healthy male subjects was used as a tool to detect, track, and quantify drug and metabolites in biologic samples.
Semen discoloration was noted in prior clinical studies, especially at higher KAE609 doses; therefore, our strategy was to collect a semen sample once from each subject postdose to further evaluate this clinical observation from data on the distribution of the parent and metabolites, which would allow assessment of potential risks on sperm.
In this article, we describe the definitive quantification of a prominent metabolite (M23) in human plasma to evaluate metabolite exposure coverage, the rationale for the source of the yellow color in semen observed in clinics, and the innovative approaches in the structural elucidation of a new human metabolite (M16) identified in plasma, urine, feces, and semen, albeit at low levels. To our knowledge, this is one of the first examples using an electrochemical approach to generate a sufficient quantity for structural elucidation of a metabolite.
Materials and Methods

Chemicals
Metabolites M23 and M16 were synthesized and coded as compounds 3 and 4, respectively. The investigational drug, [
14 C]KAE609 (300 mg; total 2.41 MBq, 65 mCi, specific activity 0.216 mCi/mg in six capsules of 50 mg), was prepared by Novartis and supplied to the investigative site as open-labeled individual subject packs. Chemical reagents (ammonium acetate, formic acid) and solvents (methanol, isopropranol, and acetonitrile) were obtained from Sigma-Aldrich (St. Louis, MO). OPTI-FLUOR liquid scintillant was purchased from Packard Instrument Co. (Downers Grove, IL). Control blank plasma samples from three individual male human subjects were purchased from Bioreclamation (Hicksville, NY).
Electrochemical Synthesis of Compound 4 (M16)
For electrochemical oxidation, a one-compartment electrochemical synthesis cell with a volume of 80 ml was used attached to a ROXY potentiostat controlled by Dialogue software (version 2.02.199; Antec Leyden B.V., Zoeterwoude, The Netherlands). This cell contained a 32-cm 2 boron doped diamond (Magic Diamond) working electrode, a platinum wire auxiliary electrode, and a Pd/H 2 (HyREF; Antec Leyden B.V.) reference electrode. The buffer solution contained 0.9 mM compound 3 dissolved in 1:1 (v/v) acetonitrile/water and 0.5% formic acid as the electrolyte to provide sufficient conductivity for the electrochemical process. A square wave pulse of +1.1 V (2 seconds) and +0.7 V (1 second) was applied over 600 minutes at room temperature. The reaction mixture was concentrated by removing the acetonitrile in vacuo, adsorbing on a solid-phase extraction cartridge (Oasis HLB 20 cc; Waters Corp., Milford, MA), and extracting with 1:1 methanol/acetonitrile, followed by lyophilization.
Supercritical fluid chromatography (SFC) purification was achieved on a Waters Prep 100q SFC System equipped with a Waters 2998 PDA detector and a Waters 3100 mass spectrometer utilizing mass spectrometry (MS)-triggered fractionation. The following equipment and conditions were used: Reprospher 100 C18-WCX column, 5 mm, 30 Â 250 mm (Dr. Maisch, AmmerbuchEntringen, Germany); flow rate, 100 ml/min; eluent A, supercritical CO 2 ; eluent B, methanol; gradient, 0 minutes 21% B and 10 minutes 26% B; column temperature, 40°C; and injection volume, 1 ml in 1:1 methanol/dichloromethane. After solvent removal, 3.3 mg of pure material 4 was obtained, corresponding to a yield of 10%. The characterization of compound 4 by high-resolution MS and nuclear magnetic resonance (NMR) is described below.
Radiation Safety for Study Subjects
The expected radiation exposure of a subject was estimated according to International Commission on Radiologic Protection (ICRP; http://www.elsevier. com/wps/find/bookdescription.cws_home/713998/description#description) guidelines. The dosimetry calculations were based on prediction of human organ exposure from conservative assumptions, as well as on extrapolation of available data on human pharmacokinetics (PK) using nonradiolabeled KAE609 and rat mass balance data using [
14 C]KAE609. The additional whole-body radiation burden in this study, due to the oral administration of 2.41 MBq (65 mCi) [ 14 C] KAE609, was calculated to be maximally 0.88 mSv. This is below the recommended beyond background dose limit for the public of 1 mSv per year and is in compliance with the ICRP guidance. The average natural radiation exposure is estimated to be approximately 2.4 mSv per year and approximately 2.0 mSv in The Netherlands, where this clinical study was conducted. For biomedical investigations in small groups of healthy subjects, an effective dose of 0.1-1.0 mSv is considered to be a minor risk (Category IIa according to ICRP 60 and ICRP 62) and therefore was acceptable.
Study Design and Conduct. This was an open-label ADME study with a single oral dose of [ 14 C]KAE609 (300 mg, 65 mCi). The study protocol was reviewed and approved by both the radiation safety and ethics committees at the investigative site. All subjects provided written informed consent. Subjects had to be healthy men aged 35-55 years, as indicated by medical history, examination, and standard safety laboratory assessments. They could not have received radiation of . 0.2 mSv for diagnostic, therapeutic, or research purposes within the prior 12 months. No other medications were allowed during the study.
Six healthy white male volunteers with a median age of 51 years were enrolled and all completed the study evaluations as planned. Dose administration was in the fasted state. Subjects who met the eligibility criteria at screening were admitted for baseline (day 21) evaluations. Subjects reported to the study center at least 18 hours prior to dosing to undergo baseline safety assessment and evaluations to confirm continued eligibility. Subjects remained domiciled from reporting to the study center on day 21 through the observation and sample (blood, plasma, urine, semen, and feces) collection period of 10-14 days postdose. Subjects were not discharged from the clinical research center until total radioactivity recovery was $85% and radioactivity was #5% of the C max in blood, with a maximum in-house observation period of 4 additional days (days 11-14) irrespective of percent recovery.
On the evening of admission, subjects received a standardized dinner followed by a small snack in the evening. Thereafter, the subjects fasted overnight for a minimum of 10 hours. On the morning of dosing (day 1), subjects underwent predose safety evaluations and provided blood, plasma, urine, and fecal samples for pharmacokinetic and metabolism assessments as specified in the assessment schedule. Subjects then received a single oral dose of 300 mg [ 14 C]KAE609, administered as six capsules (50 mg each capsule) with water. Semen collection was done at 6, 12, or 24 hours postdose, with two subjects randomized to each time point (i.e., each subject provided one sample postdose).
Safety and pharmacokinetic assessments were performed throughout the study at specified time points. Safety assessments included physical examinations, ECG results, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), and adverse event and serious adverse event monitoring.
Blood, plasma, urine, feces, and semen were analyzed for total radioactivity and for determination of KAE609 and overall metabolic profiles. Subjects were released from the study center after the collection of the last pharmacokinetic and metabolism samples (blood, plasma, urine, feces, and semen) and after all safety assessments had been completed (study completion assessments). Urine collection was stopped if daily recovery in urine was , 1% of the dose on 2 consecutive days.
Sample Preparation
Blood, plasma, urine, feces, and semen samples were collected at selected time points after a single oral dose of 300 mg [ 14 C] KAE609. All samples were received from PRA International (Utrecht, The Netherlands) and stored at 280°C until analysis (within 3 months).
Plasma for Quantification of KAE609 and M23. Blood samples were subjected to centrifugation to obtain plasma samples. Plasma samples at selected time points were extracted by protein precipitation using a 96-well plate. A 100-ml aliquot of human plasma [blank, zero, standards, quality control (QC) samples, and unknowns] and a 25-ml aliquot of internal standard solution, which contained 1000 ng/ml [ 13 C 6 ]KAE609 in 50:50 (v/v) acetonitrile/water solution, were added to each well in a 96-well plate. Then, the plate was vortex mixed briefly. A 300-ml aliquot of acetonitrile was added to each well and the plate was vortex mixed for 5 minutes. The assay plate was centrifuged at 1000 Â g for 10 minutes at 10°C. The supernatant (250 ml) was transferred and evaporated to dryness under nitrogen at 40°C. The residues were reconstituted in 200 ml 20: 80 (v/v) acetonitrile/water by vortex mixing for 10 minutes. A 5-ml aliquot was injected onto a selected column for quantification by liquid chromatographytandem mass spectrometry (LC-MS/MS).
Plasma for Metabolic Profiling of KAE609. Human plasma samples were pooled according to the area under concentration-time curve (AUC) pooling method (Hamilton et al., 1981) , using samples from 0.5, 1, 2, 3, 4, 6, 8, 24, 36, 48, 72, 96, 120 , and 144 hours. The pooled samples (10 ml) were extracted with a 40-ml mixture of acetonitrile and methanol [1:1 (v/v)] containing 0.1% acetic acid. Samples were vortex mixed and sonicated for 10 minutes prior to centrifugation. The supernatants were evaporated to near dryness under a gentle stream of nitrogen on a TurboVap LV (Zymark Corp., Taunton, MA). The resulting residues were reconstituted with 10 ml 5 mM ammonium formate containing 0.1% formic acid in water prior to LC-MS/MS analysis.
Urine and Feces for Metabolic Profiling of KAE609. Urine and fecal pools were prepared (1% of weight), with samples covering the time interval 0-72 hours postdose. The urine sample was centrifuged at 3500 rpm and 10°C for 10 minutes. The supernatant was concentrated to dryness under nitrogen at 35°C. The residue was reconstituted in 10 ml 5 mM ammonium formate with 0.1% formic acid in water prior to LC-MS/MS analysis. Each pooled fecal sample was extracted three times with 5 volumes of acetonitrile/methanol/acetic acid [50:50: 0.1 (v/v/v)]. Each extract was centrifuged at 3500 rpm for 10 minutes and the supernatants were combined. The combined supernatants were concentrated under nitrogen. Residues were reconstituted in acetonitrile/deionized water [50/50 (v/v)] prior to LC-MS/MS analysis.
Semen for Metabolic Profiling of KAE609. One semen sample was obtained from each subject at the selected time points (6, 12, or 24 hours postdose). The sample volume was variable (0.5-2.0 ml) from six subjects. Proteins were precipitated by the addition of 5-10 ml acetonitrile/methanol (1:1) containing 0.1% acetic acid to semen samples. The samples were centrifuged at 3500 rpm and 10°C for 10 minutes. The supernatants were concentrated to dryness under nitrogen at 35°C. The residues were reconstituted in 5 ml 5 mM ammonium formate containing 0.1% formic acid in water prior to LC-MS/MS analysis. Fig. 1 . Structure of KAE609 and key metabolites. KAE609 is uniformly labeled in the phenyl ring (indicated by asterisk). The numbering of M23 and M16 is for the interpretation of NMR data. Fig. 2 . Mean cumulative recovery of total radioactivity in urine and feces from human subjects. Urine and feces samples were collected up to 10-14 days from six human subjects. Aliquots of urine samples were counted directly for radioactivity. After homogenization, aliquots of fecal homogenate were combusted and counted for radioactivity. The mean cumulative recoveries of radioactivity in urine, feces, and combination are plotted against time.
For calculation of extraction recovery, an aliquot of the reconstituted sample was assayed by liquid scintillation counting (Packard Instrument Co.). Recoveries of radioactivity were approximately 93%-100% in plasma, 93% in urine extract, 75.5% in fecal extract, and 95% in semen extract, respectively.
Sample Analysis
Determination of Radioactivity. Concentrations of total radioactivity in blood, plasma, urine, fecal homogenate, and semen were measured by liquid scintillation counting. An aliquot of plasma and urine samples was counted directly for radioactivity.
An aliquot of blood samples (0.3 ml) was added to 1 ml tissue solubilizer (Solvable; Perkin Elmer, Waltham, MA) and the mixture was incubated at 60°C in a water bath for 60 minutes. After cooling in the water bath, Titriplex (0.1 M, 100 ml) was added and the sample was decolorized by adding three times a volume of 75 ml 30% hydrogen peroxide (VWR International, Radnor, PA). After incubation for 15 minutes at room temperature, the mixture was heated again for 30 minutes at 60°C in a water bath. After cooling in a water bath, 18 ml of the scintillation cocktail Ultima Gold (Perkin Elmer) was added. After vortexing mixing for at least 5 seconds, the vial was placed in the liquid scintillation analyzer for at least 35 hours before counting.
Fecal samples were weighted and water (one to two weight equivalents) was added, and the mixture was homogenized with an Ultra Turrax mixer for at least 2 minutes. Four accurately weighted aliquots of approximately 500 mg of the fecal homogenate were dried in a stove at 50°C for at least 3 hours. After the addition of combustion aid (Perkin Elmer) to the dry homogenates, the samples were combusted in a model 307 sample oxidizer (Perkin Elmer). CarboSorb-E (7 ml) was used as absorber agent for carbon dioxide. At the end of the combustion cycle, the absorber was mixed with 13 ml of the scintillant PermaFluor E. The samples were placed in the liquid scintillation analyzer at least 60 minutes before counting.
Quantification of KAE609 by LC-MS/MS. Chromatographic separation was achieved using a Mac-Mod Analytical ACE C8 (50 Â 2.1 mm, 5 mm) column (heated at 30°C). The mobile phase consisted of two solvents (A, water containing 0.1% formic acid; and B, methanol containing 0.1% formic acid). The following linear gradient was used: 35% B from 0 to 0.5 minutes, 35% B to 90% B from 0.5 to 2 minutes, hold at 90% B until 3 minutes, 90% B to 35% B from 3 to 3.2 minutes, and hold at 35% B until 4 minutes. The flow rate was 0.3 ml/min.
An API4000 mass spectrometer (AB Sciex, Foster City, CA) was used for the quantification of KAE609. Analyses were carried out using electrospray ionization in positive ion mode. The mass spectrometer was operated in multiple reaction monitoring mode. The mass transitions for KAE609 and internal standard [ 13 C 6 ]KAE609 were monitored from a precursor ion mass-to-charge ratio (m/z) of 390.2 to product ion m/z 347.1 and precursor ion m/z 396.2 to product ion m/z 353.1, respectively. The calibration curves ranged from 1 to 5000 ng/ml and QC samples were prepared at 2, 5, 400, 2000, and 4000 ng/ml. The assay accuracy and precision met the acceptance criteria set as 615%, or 620% . Blood, urine, feces, and semen samples were collected at selected time intervals from six human subjects (subject 5103 is presented as an example). After centrifugation, plasma samples were pooled according to the AUC pooling method from 0 to 120 hours or 0 to 144 hours postdose. After extraction, the pooled plasma samples, fecal homogenate, and urine and semen samples were analyzed by LC-MS/MS. ADME of KAE609, a Potent Antimalarial Agent, in Humans 675 at ASPET Journals on July 9, 2017 dmd.aspetjournals.org for the lower limit of quantification (LLOQ), percentage of bias, and percentage of the coefficient of variation.
Quantification of M23 by LC-MS/MS. Another method was developed for the quantification of M23 due to the presence of several isomeric metabolites in plasma. Chromatographic separation was achieved using a Mac-Mod Analytical ACE C18 (50 Â 2.1 mm, 5 mm) column (heated at 40°C). The mobile phase consisted of two solvents (A, 10 mM ammonium formate containing 0.2% formic acid; and B, acetonitrile containing 0.2% formic acid). The isocratic condition (40% B) was used at a flow rate of 0.3 ml/min.
An AB Sciex API4000 mass spectrometer was used for the quantification of M23. Analyses were carried out using electrospray ionization in positive ion mode. The mass spectrometer was operated in multiple reaction monitoring mode. The mass transitions for M23 (compound 3) and [ 13 C 6 ]KAE609 were monitored from precursor ion m/z 404.2 to product ion m/z 375.3 and from precursor ion m/z 396.2 to product ion m/z 353.2, respectively. The calibration curves ranged from 1 to 500 ng/ml and QC samples were prepared at 5, 50, and 500 ng/ml. The assay accuracy and precision met the acceptance criteria set as 6 15%, or 6 20% for LLOQ, percentage of bias, and percentage of the coefficient of variation.
Metabolic Profiling by LC-MS/MS
High-Performance Liquid Chromatography Method. The plasma, urine, and semen samples were subjected to two-dimensional high-performance liquid chromatography (HPLC) for sample loading and analysis with offline radioactivity detection. The fecal samples were subjected to one-dimensional HPLC analysis with online or offline radioactivity detection. The HPLC column (YMCpack, ODS-AQ/S-3mm/12 nm 50 Â 4.6 mm ID) was used for loading and the mobile phase was 3% acetonitrile in water at a flow rate of 0.6 ml/min. After loading, the eluent was switched to a separation column (Zorbax SB-C18 column, 150 Â 3.0 mm, 3.5 mm, at 35°C; Agilent Technologies) at a flow rate of 0.5 ml/min. Mobile phases consisted of solvent A [5 mM ammonium formate containing 0.1% formic acid] and solvent B [1:1 (v/v) acetonitrile/methanol containing 0.1% formic acid]. The linear gradient started at 5% B for 5 minutes, increased to 50% B from 5 to 12 minutes, to 60% B from 12 to 30 minutes, to 75% B from 30 to 40 minutes, to 85% B from 40 to 45 minutes, and to 98% B from 45 to 50 minutes. A detailed description of the three HPLC/ultraperformance liquid chromatography (UPLC) methods for comparison of compound 4 and M16 from human fecal extract can be found in the Supplemental Materials and Methods.
LC-MS Instrumentation and Operating Conditions. After HPLC separation, metabolites were identified by MS (LTQ-Orbitrap Elite; Thermo Fisher Scientific, Waltham, MA). The metabolites were interfaced with the Waters Acquity UPLC system (Milford, MA) and an online or offline radioactivity monitor. HPLC eluent was split 9:1; 450 ml/min was collected into a b-online radioactivity monitor or LumaPlates for radioactivity determination, and 50 ml/min was injected into a mass spectrometer for structure elucidation. Qualitative and quantitative analyses were carried out using electrospray ionization in positive ion mode. The ion spray voltage, capillary voltage, and tube lens offset were adjusted to achieve maximum sensitivity using the parent KAE609 in positive ion mode. The heated capillary temperature was 300°C, the source voltage was 4.5 kV, and the capillary voltage was 45 V. Analyzer Fourier transform mass spectrometry was set up with resolution 12,000 with mass accuracy maintained less than 3 ppm during the analysis. The MS/MS spectra were obtained by high-energy collision-induced dissociation of [M + H] + . The acquired data were analyzed using Xcalibur software (version 2.0; Thermo Scientific Inc.).
A detailed description of HPLC/UPLC methods for comparison of compound 4 and M16 from human fecal homogenate and NMR analysis of compound 4 (M16) can be found in the Supplemental Materials and Methods.
Data Processing
Quantification of KAE609 and Metabolites by Radiometry. Radioactive peaks were selected visually from the radiochromatogram. The radioactivity in the region encompassing the beginning and ending of the peak was summed. All further calculations were based on radioactivity.
The percentage of radioactivity (%PRA) in a particular peak, Z, was calculated as follows:
Where DPM is disintegration per minute. The concentration or amount of each component was calculated as %PRA (as a fraction) multiplied by the total concentration (nanogram equivalent per milliliter) or the percentage of dose in the excreta (the data were not adjusted for extraction recovery). Pharmacokinetic Parameters. The pharmacokinetic parameters were calculated using actual recorded sampling times and noncompartmental method(s) with Phoenix software (WinNonlin, version 6.2; Pharsight, Certara L.P., Princeton, NJ). Concentrations below the LLOQ were treated as zero for PK parameter calculations. The linear trapezoidal rule was used for AUC calculation. Regression analysis of the terminal plasma elimination phase for the determination of terminal elimination half-life (t 1/2 ) included at least three data points after C max . If the adjusted R 2 value of the regression analysis of the terminal phase was less than 0.75, no values were reported for t 1/2 , AUC inf , apparent volume of distribution during the terminal elimination phase after extravascular administration (V z /F), and apparent systemic (or total body) clearance from plasma (or blood) after extravascular administration (CL/F).
Results
Six healthy white male volunteers with a median age of 51 years were enrolled and all completed the study evaluations as planned. No significant adverse events or safety concerns were reported. Every subject reported semen discoloration, even though only two semen samples (subjects 5101 and 5104) were considered by the laboratory personnel to have a yellow color.
Mass Balance of KAE609 in Humans
After oral administration of [ 14 C]KAE609 at 300 mg (65 mCi), mass balance was achieved in all six subjects (88.8% 6 3.02% of the dose), with 3.97% and 84.9% of the administered radioactivity dose being recovered in urine and feces, respectively (Fig. 2) .
PK of KAE609 in Humans
PK parameters of KAE609 in each subject are summarized in Table 1 . The plasma concentration of KAE609 declined in a monoexponential manner. The mean C max was approximately 1780 ng/ml, with a median t max of 3.5 hours (range, 3-8 hours). The CL/F of KAE609 was approximately 4.99 l/h. The t 1/2 of KAE609 was approximately 33.4 hours. The mean Vz/F for KAE609 was 238 liters. The Vz/F value indicates that KAE609 may not be extensively distributed into tissues.
Metabolite Profiling of [14C]KAE609 in Plasma
According to the AUC pooling method (Hamilton et al., 1981) , aliquots of plasma samples at selected time intervals were combined from each subject for metabolite profiling. Representative metabolic profiles from subject 5103 in all matrices are depicted in Fig. 3 . Quantitative information on the metabolites from each subject appears in Table 2 . In all subjects, the major circulating component in plasma was KAE609, accounting for approximately 76% of the total radioactivity AUC 0-120 h . Two prominent metabolites were identified to be M18 and M23, accounting for approximately 8% and 12% of total radioactivity in the AUC 0-120 h pool, respectively. Several minor oxidative metabolites (M14, M16, and M23.5B) were also identified, each accounting for , 4% of total radioactivity AUC 0-120 h . M23.5B and M16 were at trace levels in plasma from only one and two subjects, respectively. .5B: two metabolites were coeluted and the recovery represented the mixture of two metabolites.
b The pooled urine samples were extracted from only two subjects (numbers 5103 and 5104). The semen samples were extracted and analyzed by LC-MS/MS for metabolic profiling. The HPLC separation of KAE609 and metabolites was performed using a Zorbax SB-C18 column, as described in the Materials and Methods. a Semen samples were collected from subjects 5103 and 5106 at 6 hours postdose, subjects 5101 and 5105 at 12 hours postdose, and subjects 5102 and 5104 at 24 hours postdose. ADME of KAE609, a Potent Antimalarial Agent, in Humans 677 at ASPET Journals on July 9, 2017 dmd.aspetjournals.org PK of M23, the Major Circulating Metabolite, in Humans M23 was previously identified as a human circulating metabolite of KAE609 from a first-in-human study. The structure of M23 (Fig. 1) , generated by biotransformation using compound 2 (M18) as a substrate with human recombinant CYP1A2, was elucidated by NMR (Huskey et al., 2016) . Subsequently, M23 was chemically synthesized and used as the reference standard with the internal standard ([ 13 C 6 ]KAE609) for the quantification of M23 by LC-MS/MS analysis. Thus, the concentrations of M23 were determined by both radiometric and LC-MS/MS assays in this study.
PK parameters of M23 in each subject are summarized in Table 3 . Concentrations of M23 were quantifiable as early as 1 hour postdose in all subjects and reached the maximal mean concentration of 265 ng/ml at a median t max approximately 24 hours postdose. The t 1/2 of M23 was approximately 35.3 hours. Exposure of M23 was similar among subjects 5101, 5103, 5104, and 5106; however, much lower exposure of M23 (approximately one-third of the other subjects) was observed in subjects 5102 and 5105.
Exposure of KAE609 and M23 was compared using radiometric or LC-MS/MS methods. The mean exposure of KAE609 (AUC 0-120 h approximately 75 mgEq×h/ml) by the radiometric method is comparable to that obtained using LC-MS/MS quantification (AUC inf approximately 67.0 mg×h/ml). Similarly, the mean exposure of M23 (AUC 0-120 h approximately 11.7 mgEq×h/ml) by the radiometric method was comparable to that by LC-MS/MS quantification (AUC 0-120 h approximately 16.1 mg×h/ml). The mean exposure ratio of M23 (AUC inf 18.3 mg×h/ml) to KAE609 (AUC inf 67.0 mg×h/ml) was estimated to be approximately 29%.
Metabolite Profiling of [ 14 C]KAE609 in Urine and Feces
Recovery of radioactivity from urine was less than 5% of the dose; thus, metabolic profiling was conducted from only two subjects (5103 and 5104). Urine and fecal pools were prepared and quantitative information on the metabolites from each subject appears in Table 4 . Representative metabolic profiles in urine and feces from subject 5103 are depicted in Fig. 3 , B and C, respectively. A detailed summary of KAE609 and metabolites in excreta from each subject can be found in Supplemental Tables 2 and 3. [ 14 C]KAE609 was not detected in the urine. The prominent radiolabeled components were M23 and M14, with an average value of approximately 1.4% of dose. All other metabolites were present at low levels, contributing , 0.5% of dose. M35.8 was a glucuronide based on LC-MS/MS analysis, presumably derived from M48.
KAE609 and M23 were two major components in human feces, accounting for a mean of approximately 32% and 36% of the dose, respectively. The amount of KAE609 and M23 excreted in feces varied to some extent among six subjects. Several minor metabolites were also identified, each accounting for , 2%-3% of the dose. Three minor metabolites (M16, M23.5A, and M23.5B) were not observed from previous nonclinical ADME studies. The proposed structures of metabolites are presented in Fig. 5 .
Metabolite Profiling of [ 14 C]KAE609 in Semen
Semen samples were collected at 6, 12, and 24 hours postdose (n = 2 per time point and only one collection per subject). A representative metabolic profile of a semen sample from subject 5103 is depicted in Fig. 3D . Quantitative information on the metabolites from each subject appears in Table 5 . The amount of total radioactivity excreted in semen from each subject was minimal, ranging from 832 to 15,177 ngEq (,0.005% of the radioactivity dose). The most abundant radiolabeled component in semen was M23, accounting for approximately 56% of total radioactivity in semen. Two prominent radiolabeled components were KAE609 and M16, accounting for approximately 12% and 10% of total radioactivity in semen. A few minor metabolites were also identified, each accounting for approximately 3%-6% of total radioactivity in semen. Figure 4 presents the mean exposure of KAE609 and metabolites in plasma and mean recovery of KAE609 and metabolites in feces, urine, and semen. KAE609 was the major circulating component, accounting for approximately 76% of the total AUC. M23 and M18 were two prominent metabolites, accounting for approximately 12% and 8% of the total AUC. However, both KAE609 (approximately 32% of dose) and M23 (approximately 36% of the dose) were major components in human feces, the primary route of elimination. KAE609 was not detected in urine and M14 and M23 were two minor metabolites excreted in urine. Only a trace amount of radioactivity was excreted in semen (,0.005% of the dose). M23 was the major component, followed by KAE609 and M16 in semen.
Overall Metabolism of [ 14 C]KAE609 in Plasma and Excreta
Structural Characterization of [ 14 C]KAE609 and Metabolites by LC-MS/MS
Structural characterization of metabolites was based on their elemental composition derived from accurate mass measurements and fragment ions in their data-dependent MS 2 and MS 3 mass spectra. Comparison of metabolite fragment ions with those of KAE609 allowed the assignment of regions of biotransformation. The accurate mass, elemental formula, and diagnostic fragment ions of each metabolite are summarized in Table 6 and proposed structures of the metabolites are presented in Fig. 5 . Structural elucidation of M16, M18, M23, and M37 was based on LC-MS/MS and NMR analysis and was further confirmed by chemical synthesis (Huskey et al., 2016) .
Detailed description of structural elucidation of compound 4 by NMR can be found in the Supplemental Results and Supplemental Table 1 . Compound 4 shared the identical molecular ion and the identical product ion spectra with M16 from human feces. In addition, M16 and compound 4 shared identical elution times in three HPLC/ UPLC systems tested. A detailed description of HPLC coelution can be found in the Supplemental Results. Therefore, we concluded that compound 4 is M16.
Metabolite Pathways of [ 14 C]KAE609 in Humans
An overall metabolic pathway for KAE609 in humans is summarized in Fig. 5 . KAE609 was well absorbed and extensively metabolized in humans, such that unchanged KAE609 in feces represented approximately 32% of the dose. KAE609 underwent C-C bond cleavage and a 1,2-acyl shift to form ring expansion metabolite M37. This novel biotransformation was catalyzed by CYP3A4. M37 was oxidized to M18 by CYP3A4 and was further hydroxylated to M23 by CYP1A2 (Huskey et al., 2016) . M23 was further oxidized to M16 by all 19 commercially available cytochrome P450 (P450) enzymes, albeit at low levels (data not shown). KAE609 also underwent oxidation to M40 with 2 mass units lower than that of KAE609 and one metabolite (M48) with 4 mass units lower than that of KAE609. KAE609 and these oxidative metabolites were further hydroxylated and/or oxygenated to numerous minor metabolites (M29.8, M34, M14, M21.8, M23.5A, M24, M32, and M35). M48 underwent glucuronidation to M35.8 and M23
.5B presumably was a carbamate metabolite of KAE609.
Discussion
KAE609 is an antimalarial agent in development Meister et al., 2011; Spillman et al., 2013 ). An oxidative metabolite, M23, was identified in human plasma; however, M23 was not detected in rat and dog plasma (Huskey et al., 2016) . M23 may pose concerns for metabolite exposure coverage (see U.S. Food and Drug Administration 2008 , and 2012 guidance, available at http://www.fda.gov/cder/guidance/index.htm and http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm). Our strategy was to conduct an investigation of the human ADME early in development to define the metabolite pathways of KAE609, to elucidate potential preclinical safety exposure concerns, and to determine the potential effect of intrinsic and extrinsic factors on KAE609.
A single oral dose of 300 mg [ 14 C]KAE609 was well tolerated by all six subjects and no significant adverse events were reported. KAE609   TABLE 6 Fragmentation patterns of KAE609 and metabolites Structural characterization of metabolites was carried out by LC-MS/MS analysis. The proposed structures of the metabolites were based on their elemental composition derived from accurate mass measurements and fragment ions in their data-dependent MS 2 and MS 3 mass spectra. Comparison of metabolite fragment ions with those of KAE609 allowed the assignment of regions of biotransformation, as presented in Figure 5 . was absorbed with a median t max of approximately 3.5 hours and a C max of approximately 1780 ng/ml. Mean clearance (CL/F) was approximately 5 l/h, suggesting that KAE609 is a low clearance drug. The pharmacokinetic parameters of KAE609 (Table 1) were in good agreement with the data obtained from other clinical studies, with the exception that the t 1/2 of KAE609 reported in this study was approximately 33 hours, which is longer than that estimated in other clinical studies (approximately 24 hours). This observation was attributed to the sensitive quantitative assay and long collection time intervals (up to 312 hours postdose) in our study. Similar to humans, the PK of KAE609 also had a long terminal half-life (8.2-10.9 hours) and low plasma clearance (0.201-0.252 l/h per kilogram) and good oral absorption (72.5%-100%) in rats and dogs (Huskey et al., 2016) . Radioactivity (KAE609 and metabolites) disappeared slowly from the blood and plasma, with a mean t 1/2 of approximately 41 hours and 47 hours, respectively, indicating a slower elimination of total radioactivity compared with the parent (approximately 33 hours) (data not shown). The higher radioactivity in plasma relative to whole blood suggests that drug-related radioactivity has no special affinity and distribution to red blood cells (data not shown). Plasma protein binding of KAE609 is known from previous studies to be high ($99.7% in humans).
The most abundant radioactive component in plasma was KAE609, accounting for approximately 76% of the total plasma radioactivity (pooled from 0 to 120 hours or from 0 to 144 hours). M23 was the major circulating metabolite, accounting for approximately 12% of the total plasma radioactivity. Several minor oxidative metabolites (M14, M16, M18, and M23.5B) were also identified, each accounting for approximately 3%-8% of the total plasma radioactivity. M23 was further quantified by LC-MS/MS using reference compound 3 and internal standard ([ 13 C 6 ]KAE609). The t 1/2 of M23 was comparable to that of KAE609 (approximately 35 hours). Exposure (AUC inf ) of M23 was estimated to be approximately 29% of KAE609.
Exposure of M23 was greater than 10% of total radioactivity in plasma; thus, safety evaluation of M23 in nonclinical species is planned according to guidance recommendations (see U.S. Food and Drug Administration 2008 , and 2012 guidance, available at http://www.fda.gov/cder/guidance/index.htm and http://www.fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ default.htm). M23 exposure was greater than 25% of KAE609 exposure; thus, evaluation of in vitro drug-drug interaction potential of M23 is in progress. Our investigation of the human ADME early in development proved to have significant effect on subsequent preclinical safety evaluations for clinical development.
After oral administration of [ 14 C]KAE609, the recovery of total radioactivity was greater than 85% of the dose in excreta of six subjects within 14 days postdose; these findings indicated that, in all likelihood, significant prolonged tissue retention of radioactivity was not occurring. Radioactivity was excreted slowly, consistent with the long halflife of total radioactivity in blood and plasma. Fecal excretion (approximately 85% of the dose) was the primary route of elimination of KAE609 and its metabolites. KAE609 and M23 were two major components recovered in feces, accounting for approximately 32% and 36% of the dose, respectively. Thus, KAE609 was well absorbed (.68%) and extensively metabolized in humans.
Although it is not a common practice to collect semen in human ADME studies, detection of drugs and their metabolites in semen has been reported previously, particularly in patients with HIV (Ette et al., at ASPET Journals on July 9, 2017 dmd.aspetjournals.org
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1988; Taylor and Pereira, 2001; Avery et al., 2013) . Semen was evaluated since subjects in prior studies had reported semen discoloration after taking KAE609 at higher doses. Further investigation clarified the potential cause of the discoloration and distribution of KAE609 and its metabolites. Semen samples were collected once from each subject at 6, 12, or 24 hours postdose (n = 2 per time point). Total radioactivity excreted in semen was negligible, accounting for , 0.005% of the dose. M23 was the major component in semen, accounting for approximately 56% of the total radioactivity, followed by KAE609 and M16 at approximately 12% and 10% of the total radioactivity.
The source of the color of M18 and M23 was attributed to their extended conjugated systems of double bonds in the structures (Huskey et al., 2016) . In this human ADME study, M23 and M18 were identified to be the prominent radiolabeled components in semen, which explained the previous observation of colored semen reported in clinics. Further evaluation of semen samples did not indicate any abnormalities in sperm counts and sperm mobility.
M16 was detected in semen, accounting for 10% of total radioactivity excreted; therefore, structural elucidation of M16 was further pursued. Based on product ion spectra, M16 was the oxidative product of M23. We incubated compound 3 (M23) with a panel of 19 human recombinant P450 enzymes. All P450 enzymes were capable of generating M16, albeit at very low levels. Because of the low yield by P450 enzymes, it is not feasible to generate a sufficient quantity of M16 using bioreactions for structural elucidation. Our attempt to isolate M16 from human urine and feces also produced an insufficient quantity. Thus, an alternative approach using electrochemical synthesis of M16 was explored.
Electrochemistry has been proposed as a quick and simple tool to prepare human metabolites (Faber et al., 2014) . It is mostly used to prepare hydroxylated metabolites in the benzylic position or in aromatic rings, provided that it is activated by electron donating groups, such as phenols, ethers, or anilines (Jurva et al., 2003) . Despite the high number of investigated compounds, very few studies have prepared sufficient amounts for NMR analysis (Stalder and Roth, 2013; Fredenhagen et al., 2014) . In our hands, electrochemistry is especially useful for compounds that are sparingly water soluble and that therefore are not reactive in aqueous enzyme reactions (Schroer et al., 2010) . Operation under constant voltage, rather than constant current, frequently gives higher yields because overoxidation is reduced, but it leads to longer reaction times. Because the proposed structure of M16 suggested benzylic oxidation, electrochemical production of reference material was undertaken. A boron doped diamond electrode under acidic conditions gave the desired product in 10% yield. Surprisingly, the oxidation proceeded stereoselectively, because the hydroxyl radical attacked from the opposite site of the neighboring methyl group. Stereoselective electrochemical allylic oxidation of cholesteryl acetate has been described (Okamoto et al., 2004) .
The metabolic pathway of KAE609 was proposed (Fig. 5) . KAE609, a spiroindolone derivative, undergoes an unusual C-C bond cleavage, followed by an acyl 1,2 shift to form a ring expansion structure M37. This novel biotransformation reaction was catalyzed by CYP3A4 (Huskey et al., 2016) . M37 was subsequently oxidized to M18 by CYP3A, hydroxylated to M23 by CYP1A2, and further hydroxylated to M16 by all 19 P450 enzymes tested. KAE609 also underwent oxidation to M40 with 2 mass units lower than that of KAE609 and one metabolite (M48) with 4 mass units lower than that of KAE609. KAE609 was directly hydroxylated to form two metabolites (M29.8 and M34). Two metabolites (M40 and M48) were further hydroxylated to several metabolites (M14, M21.8, M23.5A, M24, M32, and M35). One glucuronide (M35.8) was also identified in urine. Of note, M37 was the primary metabolite of KAE609 in humans even though M37 was not detected in any matrices in this study.
Metabolism of KAE609 was qualitatively similar but quantitatively different across species. The major metabolite via CYP3A was M37 in rats and M23 in dogs and humans, which is formed from M18 by CYP1A2 (M18 was formed from M37 via CYP3A). M23 was detected in rat and dog feces but not in plasma. We hypothesize that the quantitative differences across species are probably secondary to the known differences in relative amounts of the different P450 enzymes in each species and potentially to a difference in transporters.
Two observations support a transporter difference hypothesis. In dogs, a continuous intravenous infusion of M23 to achieve a plasma M23 exposure similar to that found in humans after oral dosing of KAE609 still yielded a dog semen concentration that was approximately 300-fold below that found in humans. M23 was the major fecal metabolite in both humans and dogs; therefore, M23 formed from hepatic metabolism was distributed to blood and bile in humans, but only to bile in dogs.
Overall, a single 300-mg dose of KAE609 was generally safe and well tolerated in these healthy male subjects. There were no serious or significant adverse events, and no clinically significant laboratory abnormalities were reported in this study. KAE609 is mainly excreted into feces with no urinary excretion. In contrast with dog and rat ADME studies, M23 is the major metabolite found in plasma, feces, and semen in humans.
